Brief: US FDA panel votes against accelerated approval of Intercept's fatty liver drug

Intercept Pharmaceuticals

19/05/2023 21:56

May 19 (Reuters) - Intercept Pharmaceuticals Inc
 ICPT.O :
    * US FDA ADVISERS SAY BENEFITS OF INTERCEPT'S DRUG DO NOT
OUTWEIGH
RISKS IN NASH PATIENTS WITH FIBROSIS BASED ON CURRENT DATA
    * US FDA ADVISERS VOTE TO DEFER APPROVAL OF INTERCEPT'S DRUG
FOR
NASH PATIENTS WITH LIVER FIBROSIS UNTIL MORE DATA IS AVAILABLE


Further company coverage:  ICPT.O 

 ((Reuters.Briefs@thomsonreuters.com;))